See other companies on Welcome to the Jungle
Miroculus
Automated NGS microfluids processing platform
- 21-100 employees
- Healthcare
- B2B
- Enterprise
- Manufacturing
- Analytics
- Biology
- Automation
- Science
- MedTech
- China Basin, San Francisco, CA
Jump to section
Company mission
To advance science and improve lives faster, together.
Our take
Traditional methods of processing complex next-generation sequencing (NGS) microfluidics are expensive and require lengthy set up times to automate protocols. Miroculus’s Miro Canvas is a compact, easy-to-use digital microfluidics platform that enables on-demand automation of complex NGS sample preparation protocols.
With the company’s platform, users can simplify, automate, and scale down complex NGS library prep, improving consistency and eliminating the need for robotics. The scalable platform allows labs like Rady Children’s Institute for Genomic Medicine to rapidly process whole genome sequencing for critically ill infants, leading to better health outcomes and lower medical costs.
The company has partnered with Element Biosciences, integrating its AVITI platform and applications with Miro Canvas, boosting the efficiencies of both platforms to further increase NGS access and choice. With funding from lead investor, Cota Capital, Miroculus is working to expand its partnerships and commercial teams.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Healthcare & Dental Coverage
- 401(k) Matching
- Unlimited PTO
Company values
- Humility - We cultivate curiosity. We operate in pursuit of continuous learning and improvement. We are neither above nor below anyone else.
- Solidarity - We are a diverse, inclusive clan. We stand together, strengthened by our diversity of experiences, backgrounds and thought. We fail and win as one
- Commitment - We are fueled by Meraki. Our passion, dedication and care drives the pursuit of our mission, the quality of our products, and how we advocate for our customers
Funding (last 2 of 6 rounds)
Feb 2021
$45m
SERIES B
Aug 2019
$2.4m
SEED
Total funding: $67.5m
Leadership
Alejandro Tocigl
(CEO)Previous CEO of MICOMO S.A.. Also worked as Director of New Business Development at Fundación Chile.
Fae Christodoulou
(CSO)Postdoctoral fellow at both the Biomedical Research Foundation of the Academy of Athens & EMBL. Previous Junior Project Manager at Biopolitics International Organization.